Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, submitted an application with Japanese regulators for Trerief (zonisamide) for the treatment of parkinsonism in dementia with Lewy bodies. The application is based on a 351-patient phase III trial, which showed two different doses of Trerief both produced a statistically significant improvement on the Unified Parkinson's Disease Rating Scale compared to patients who received placebo.